Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Iemand anders meer info over Deutsche Bank (het aandeel)? Lijkt interessant en laag gewaardeerd, alhoewel de banksector vandaag natuurlijk slecht ligt. Onderstaande analyse is van Zacks vandaag: Deutsche Bank AG (DB) is currently trading at an attractive discount to both the overall market and its investment banking peer group. Furthermore, the company’s strong financial performance is supporting the stock’s year-to-date gain of 10.1%. Full Analysis Deutsche Bank AG provides a range of investment banking products and services worldwide. The company operates through three divisions: Corporate and Investment Bank (CIB), Private Clients and Asset Management (PCAM), and Corporate Investments (CI). Founded in Berlin in 1870, the company has grown from its origins as a trade relation facilitator, to a global investment banking powerhouse with 2006 revenues of €28.3 billion. On May 8, the Zacks #1 Rank stock reported first-quarter earnings of €2.12 billion, up from €1.64 billion in the year-ago period and €320 million above expectations. The firm’s investment banking business contributed significantly to the quarter, with a 10% rise in pretax profit to €2.2 billion. Also, revenues from sales and trading rose 16% to €5.1 billion. While the firm’s consumer banking profit slipped 3%, 558,000 new private clients were added during the quarter, most of which came from the acquisition of Berliner Bank. Chief Executive Josef Ackermann commented, "We saw a particularly strong performance in equity derivatives, credit trading and foreign exchange, where the annual Euromoney poll ranked us number one in the world for the third successive year." Furthermore, “Ongoing consolidation of our industry, including cross-border mergers in Europe, may create changes in our competitive landscape.” Full-year earnings estimates have risen from $13.96 three months ago, to $15.45 currently. In addition, the company is ranked a number one out of 41 companies in the Foreign Banks category, which itself ranks an attractive 38 out of 217 industries. Furthermore, Deutsche Bank’s ROE of 19.7% exceeds the industry average of 16.3%. DB is currently trading at a valuation of 9.5x current fiscal-year estimated earnings, well below the comparable S&P 500 market and industry average multiples 16.2x and 13.3x, respectively. In addition, the company is trading at 8.9x next fiscal-year estimated earnings, also below the market multiple and industry average. Lastly, the company has a price-to-book ratio of 1.8, compared to 4.5 for the market and 2.8 for the industry. Year-to-date, DB has gained over 10%, outperforming both the S&P 500 return of 5.9% and most of its peer group in the investment banking category.
Lijkt indeed een mooie om mn AAB's te vervangen. Div. ren. (2008 exp)4,5% Prima graph,koers test 2000 high terug. Yes,kckwww.boursorama.com/graphiques/graphiq...
Op MSN Money vind ik dit terug: Debt/Equity Ratio 8.60 (ING is bvb. Debt/Equity Ratio 3.08) Dit is de volledige balance sheet:finance.yahoo.com/q/bs?s=DB&annual Zorgelijk, of niet?
Ing is 70% verzekeringen,daarom zullen ze het wel zo slecht doen afgelopen jaar. Niet te vergelijken dus. Cijfers finnen kan ik helaas niets over zeggen. Mischien dat de Moody's credit rating wat zegt.
Balance Sheet Total Cash (mrq): 1.51 T Total Debt (mrq): 426.29B Eén biljoen(1 Trillion)in de plus lijkt me?
Krijgt mee klappen, maar publiceerde vandaag wel excellente cijfers. WPA voor 2007 waarschijnlijk rond 14, aandeel staat momenteel 98 = K/W van 7; als je dat naast de winstgroei zet, tja... Deutsche Bank reports second quarter 2007 net income of EUR 1.8 billion, up 31% • Income before income taxes of EUR 2.7 billion, up 32% • Total revenues of EUR 8.8 billion, up 27% • Pre-tax return on average active equity of 36% for the second quarter, 40% for the first six months • Diluted earnings per share of EUR 3.60 for the second quarter, up 48%, and EUR 7.86 for the first six months, up 41% • Net new money of EUR 13 billion FRANKFURT AM MAIN, 1 August 2007 – Deutsche Bank (XETRA: DBKGn.DE / NYSE: DB) reported income before income taxes for the second quarter 2007 of EUR 2.7 billion, up 32% versus EUR 2.0 billion in the second quarter 2006. Net income was EUR 1.8 billion, up 31% versus EUR 1.4 billion in the prior year quarter. Pre-tax return on average active equity was 36%, versus 33% in the second quarter 2006, on average active equity which was up by EUR 5.3 billion, or 22%, over the prior year quarter. Diluted earnings per share were EUR 3.60, up 48% versus the prior year quarter. Per the bank’s target definition, which excludes certain significant gains and charges, pre-tax return on average active equity was 35%. For the first six months of 2007, income before income taxes was EUR 5.9 billion, up 26% versus the first six months of 2006. Net revenues were EUR 18.4 billion, up 23%, while net income rose 30% to EUR 3.9 billion. Pre-tax return on average active equity was 40%, compared to 38% in the first half 2006, and diluted earnings per share rose 41% to EUR 7.86. Per target definition, pre-tax return on average active equity was 38%. Dr. Josef Ackermann, Chairman of the Management Board, said: “After an excellent first quarter, we delivered another outstanding quarterly result, with significant earnings growth over the same period last year. All our business divisions contributed to this growth. As a result, we delivered a very strong first half year, clearly demonstrating the power and resilience of our platform.” He added: “Looking forward, uncertainties persist in the world’s financial markets in the short term. Some areas of the credit markets may continue to experience turbulent conditions, and investors may adopt a more conservative stance toward leveraged finance. Our business model which benefits from rigorous risk management and independent control processes is structured to deliver performance also in the face of such challenges. We have consistently adopted a prudent approach to risk-taking, and the current environment is no exception. We firmly believe that these qualities will enable us to continue to perform strongly.” Group Highlights Net revenues for the second quarter 2007 were EUR 8.8 billion, up 27% versus the second quarter 2006, reflecting year-on-year growth in all business divisions. In the Corporate and Investment Bank (CIB), revenues in Sales & Trading rose 34% to EUR 4.3 billion, a second-quarter record, driven by broad-based performance across both Debt and Equities. Revenues in Sales & Trading (Debt and other products) rose 18% to EUR 2.9 billion, reflecting strong performances in credit products and emerging markets debt. Revenues in Sales & Trading (Equity) rose 89% to EUR 1.4 billion, reflecting strong year-on-year growth across all customer-oriented businesses and a rebound in designated proprietary trading. Both Origination and Advisory recorded best-ever quarterly revenues. Origination revenues rose 12% to EUR 638 million with strong growth in equity and investment grade debt, while advisory revenues rose 63% to EUR 256 million against a backdrop of strong M&A activity. Revenues in Global Transaction Banking rose 16% to EUR 656 million, reflecting growth in Trust & Securities Services and Cash Management. In Private Clients and Asset Management (PCAM), revenues were up 11% to EUR 2.6 billion. In Private & Business Clients (PBC), revenues were EUR 1.4 billion, up 15%, reflecting the acquisition of Berliner Bank and norisbank, together with organic revenue growth. In Asset and Wealth Management (AWM), revenues rose 7% to EUR 1.1 billion. Performance fees in real estate asset management rebounded from the first quarter, although they remained lower than the exceptional levels of the second quarter 2006, while revenues in retail asset management recorded year-on-year growth. Revenue growth in Private Wealth Management (PWM) reflected both organic expansion and the acquisition of Tilney in the U.K. Revenues in Corporate Investments (CI) rose 62% to EUR 259 million, reflecting a net gain from a sale and leaseback transaction related to bank-occupied premises and dividends from industrial holdings. Provision for credit losses in the second quarter was EUR 81 million, down from EUR 98 million in the first quarter and essentially unchanged from EUR 82 million in the second quarter 2006. In PCAM, provisions were EUR 124 million, up from EUR 94 million in the second quarter 2006, reflecting the aforementioned acquisition of norisbank and Berliner Bank and continued organic growth in PBC’s loan book. This increase was offset by higher CIB releases and recoveries compared to the prior year quarter. Noninterest expenses for the quarter were EUR 6.0 billion, up 25% versus the second quarter 2006. Compensation and benefits expenses for the quarter rose 27% to EUR 3.9 billion, reflecting an increase in performance-related compensation in line with strong business results and a rise in staff numbers resulting from both acquisitions and organic growth. Amortization of equity compensation was higher than in the prior year quarter but lower than in the first quarter of 2007. Non-compensation expenses for the quarter rose 20% to EUR 2.1 billion, reflecting several contributing factors, including acquisitions, higher litigation provisions, technology expenditures and other expenses driven by higher business volumes. The cost-income ratio for the quarter was 68%, down from 69% in the prior year quarter. The ratio of compensation and benefits to revenues was 44%, unchanged from the second quarter 2006, while the ratio of non-compensation expenses to revenues was 24%, down from 26% in the prior year quarter. Income before income taxes for the quarter was EUR 2.7 billion, up 32% versus the second quarter 2006. Pre-tax return on average active equity was 36%, compared to 33% in the second quarter 2006. Per target definition, which excludes certain significant gains (net of related expenses) of EUR 131 million in the current quarter, pre-tax return on average active equity was 35%, versus 33% for the prior year quarter, in which no such gains or charges were reported. Net income for the quarter was EUR 1.8 billion, up 31% versus the prior year quarter. Diluted earnings per share were EUR 3.60, up 48% versus EUR 2.44 in the second quarter 2006. The increase of diluted earnings per share in the current quarter benefited from the modification, in late 2006, of certain derivatives contracts, related to trading in Deutsche Bank shares. Excluding this effect, the increase in diluted earnings per share over the prior year quarter would have been 32%. The effective tax rate for the quarter was 34%, unchanged to the prior year quarter. The BIS Tier 1 ratio was 8.4% at the end of the quarter, within
Bookie schreef:
Krijgt mee klappen, maar publiceerde vandaag wel excellente cijfers. WPA voor 2007 waarschijnlijk rond 14, aandeel staat momenteel 98 = K/W van 7; als je dat naast de winstgroei zet, tja...
Gekocht. KW volgens Bourso 8,3
kck schreef:
[quote=Bookie]
Krijgt mee klappen, maar publiceerde vandaag wel excellente cijfers. WPA voor 2007 waarschijnlijk rond 14, aandeel staat momenteel 98 = K/W van 7; als je dat naast de winstgroei zet, tja...
[/quote]
Gekocht.
KW volgens Bourso 8,3
Me too, JR
Bookie schreef:
In addition, the company is trading at 8.9x next fiscal-year estimated earnings, also below the market multiple and industry average.
Dat hangt er nogal vanaf welke industry je ze in plaatst. Algemene bank of investment bank. DB lijkt me duidelijk meer in het laatste profiel passen. Dan zijn ze met 8.9x FY'08 niet echt goedkoop te noemen: CS 9.1x C 9.1x UBS 9.1x JPM 9.0x DB 8.9x GS 8.4x MER 7.9x BSC 7.7x MS 7.4x LEH 7.4x
BJL schreef:
[quote=Bookie]
In addition, the company is trading at 8.9x next fiscal-year estimated earnings, also below the market multiple and industry average.
[/quote]
Dat hangt er nogal vanaf welke industry je ze in plaatst. Algemene bank of investment bank. DB lijkt me duidelijk meer in het laatste profiel passen. Dan zijn ze met 8.9x FY'08 niet echt goedkoop te noemen:
CS 9.1x
C 9.1x
UBS 9.1x
JPM 9.0x
DB 8.9x
GS 8.4x
MER 7.9x
BSC 7.7x
MS 7.4x
LEH 7.4x
Zijn wel Duitsers,heb inderdaad ook naar CS en UBS gekeken.
jrxs4all schreef:
Me too,
JR
JR, heb ook gekocht gister en vandaag iSh Epra,ter vervanging vd SD trackers. 25% in de min in een paar maand ofzo. kck
kck schreef:
[quote=jrxs4all]
Me too,
JR
[/quote]
JR,
heb ook gekocht gister en vandaag iSh Epra,ter vervanging vd SD trackers.
25% in de min in een paar maand ofzo.
kck
Heb vorige week de SD trackers ook verkocht. Deze week puts RD en ING geschreven, denk niet dat ik ze binnenkrijg maar dan toch de premie opgestreken. Nu dus DB, ik ga wel weer de SD trackers terugkopen. De sterke daling kwam met name door de financials en ik verwacht daar ook weer de grootste stijging. Gisteren en vandaag trouwens flinke outperformance van de SD index tov Eurostoxx. Dat is voor het eerst in weken, JR
kck schreef:
KW volgens Bourso 8,3
Ja, was maar een indicatie volgens eigen rekenen. Gebruik makend van winst EUR 7.86 voor eerste halfjaar, en laatste kwartaal 3.60 (= 12.5% boven verwachting), neem ik een winst van 14 euro over heel het jaar (dwz: 3 euro voor volgende 2 kwartalen). Misschien te optimistisch, maar ik denk dat die 8.3 toch nog moet bijgesteld worden om de nieuwe cijfers te weerspiegelen. Wat betreft particuliere bank of niet: ik ben particuliere klant, dus voor mij... :-) "Deutsche Bank is het grootste bankconcern in Duitsland en telt wereldwijd tot de leidende aanbieders van financiële dienstverlening. De Deutsche Bank biedt haar klanten een breed palet bankdiensten aan. De particuliere klanten wordt een complete financiële dienstverlening aangeboden, wat onder andere betalingsverkeer, beleggingsadvies en vermogensbeheer omvat. Het bedrijfsleven en institutionele klanten bied de bank een omvattend spectrum van het afwikkelen van het betalingsverkeer, ondernemingsfinanciering, begeleiding van een beursgang en het geven van advies bij overnames en fusies. Bovendien neemt de Deutsche Bank een leidende positie in op het gebied van de internationale handel in aandelen, obligaties, valuta, geldmarkt. Deutsche Bank heeft wereldwijd vestigingen waar meer dan 63.000 werknemers actief zijn. Ongeveer 40% daarvan is werkzaam in Duitsland"
Op www.manager-magazine.de zijn ze dan weer wat kriegel dat Ackermann NIET op concrete vragen duidelijke antwoorden geeft. Het magazine vreest zelfs risico's van meer dan 100 miljoenen. Wie deel 2 wil lezen moet zelf maar eens naar die website gaan. Posting is bedoeld om aan te geven waarom er toch nog scepsis is omtrent dit goed presterende bankaandeel. DEUTSCHE BANK Rekordgewinn, aber die Skepsis bleibt Ungeachtet der US-Hypothekenkrise hat die Deutsche Bank das beste zweite Quartal ihrer Geschichte hinter sich. Mit Blick auf mögliche Risiken gibt Vorstandschef Josef Ackermann Entwarnung, weicht konkreten Fragen aber aus. Experten erwarten, dass der Bank allein im Geschäft mit US-Hypotheken Belastungen in dreistelliger Millionenhöhe drohen. Frankfurt am Main - Der Gewinn der Deutschen Bank ist im zweiten Quartal um fast ein Drittel auf 1,78 Milliarden Euro und übertraf deutlich die Erwartungen der Analysten. Die Sorgen der Anleger vor den Folgen der Krise konnte Bank-Chef Josef Ackermann am Mittwoch dennoch nicht ausräumen. Die Aktie brach um bis zu 3,5 Prozent auf 97,40 Euro ein. © AP Großansicht "Sehr vorsichtig mit Risiken": Vorstandschef Ackermann Analysten kritisierten, das Management sei konkreten Fragen ausgewichen. Die Deutsche Bank sei gegen Verluste nicht immun. Ackermann erklärte, dass die US-Hypothekenkrise aus Sicht der Bank zwar Auswirkungen auf das Geschäftsumfeld habe, aber keine grundlegende Umwälzung darstelle. Die Bank sei in der Vergangenheit mit der Übernahme solcher Risiken sehr vorsichtig gewesen. "Daher sind wir fest davon überzeugt, dass diese Disziplin es uns erlauben wird, weiterhin gute Ergebnisse zu erwirtschaften", erklärte er. Viele Fragen bleiben offen Analysten bemängelten, viele Fragen seien offen geblieben. "Das ist natürlich schade - gerade in Situationen, in den die Unsicherheit groß ist", sagte Dieter Hein von Fairesearch. "Die Leute haben die Sorge, dass sich da draußen große Risiken befinden", ergänzte Analyst Alan Webborn von Societe Generale. "Niemand weiß letztlich, wann die Musik zu spielen aufhört und wer dann ohne einen Stuhl zum Sitzen dasteht." Anfang der Woche war die IKB Mittelstandsbank in Bedrängnis geraten, weil sich ein Fonds der IKB mit US-Hypothekenkrediten verspekuliert hatte. Die staatliche Förderbank KfW musste ihr zur Seite springen. Die Finanzaufsicht BaFin erklärte zwar am Mittwoch, sie sehe in diesem Zusammenhang keinen Anlass für weitere Sonderprüfungen unter den deutschen Banken. In Presseberichten hieß es aber, einzelne Institute hätten der IKB millionenschwere Kreditzusagen gemacht. Andere sollen ebenfalls mit den schlecht gesicherten Hypothekenkrediten spekuliert haben. Standard & Poor’s sieht Gefahr für Banken Zugleich könnten sich die Renditebringer der Vergangenheit - die kreditfinanzierten Übernahmen - zu einer ernsthaften Gefahr in den Bilanzen der Banken entwickeln. Finanzinvestoren stemmen den Kauf von Unternehmen mit bis zu 80 Prozent Fremdkapital – finanziert durch große Geschäftsbanken, die derlei Kredite syndizieren. Für gewöhnlich bündeln die Banken die Kredite und reichen sie an den Kapitalmarkt weiter. Angesichts der Kreditkrise am US-amerikanischen Hypothekenmarkt reagieren die Investoren aber zunehmend skeptischer. Die Konsequenz: Die Banken bleiben auf den Risiken sitzen. "Harte Landung nicht auszuschließen" Sollte sich die Krise an den internationalen Kreditmärkten ausweiten, drohe nach Einschätzung der Ratingagentur Standard & Poor’s auch eine Gefahr für die Bonität der Banken. Dies gelte vor allem dann, wenn die von Finanzinvestoren übernommenen Unternehmen in die Insolvenz gingen oder sich die Krise am US-Hypothekenmarkt ausweiten sollte. "Man kann eine harte Landung nicht völlig ausschließen", zitiert die Internetausgabe des Handelsblatt am Mittwoch aus der Studie. Mehr zum Thema · Kreditklemme: Welche Milliardendeals jetzt wackeln (01.08.2007) · Übernahme: Deutsche Bank kauft Abbey Life (31.07.2007) · Deutsche Bank: Rückzug aus dem Iran (28.07.2007) Wie stark Banken nun von der Krise an den Kreditmärkten tatsächlich betroffen sind, ist schwer zu beziffern. Die meisten Institute schweigen zu ihrem Engagement bei kreditfinanzierten Übernahmen. Noch weisen sie aus, wir stark sie in dem riskanten Markt für US-Hypotheken involviert sind. Experten der US-Investmentbank von Morgan Stanley haben gleichwohl versucht, sich anhand des verfügbaren Zahlenmaterials darüber ein Bild zu machen. Weiter zu Teil 2: Wie tief die Deutsche Bank drinsteckt
ffff schreef:
Op
www.manager-magazine.de zijn ze dan weer wat kriegel dat Ackermann NIET op concrete vragen duidelijke antwoorden geeft. Het magazine vreest zelfs risico's van meer dan 100 miljoenen.
Wie deel 2 wil lezen moet zelf maar eens naar die website gaan.
Ik kan deel 2 niet vinden op die link. Maar lees ook even deze info:www.bloomberg.com/apps/news?pid=newsa... JR
ffff schreef:
Weiter zu Teil 2: Wie tief die Deutsche Bank drinsteckt
Tja spul is niet voor niets in de uitverkoop.
JR, Als je deel 1 op die website leest dan kun je op het eind van dat artikel deel 2 aanklikken. Overigens: goede website. Peter
ffff schreef:
JR,
Als je deel 1 op die website leest dan kun je op het eind van dat artikel deel 2 aanklikken.
Overigens: goede website.
Peter
Peter, ik krijg het artikel niet te zien als ik die link aanklik. Er verschijnt een soort startpagina met per letter allerlei links naar online tijdschriften, JR
"http://www.manager-magazin.de/geld/artikel/0,2828,497561-2,00.html"
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
865,36
0,00%
EUR/USD
1,0639
-0,05%
FTSE 100
7.877,05
0,00%
Germany40^
17.751,90
-0,48%
Gold spot
2.381,83
+0,10%
NY-Nasdaq Composite
15.601,50
-0,52%
Stijgers
Dalers